Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 28, 2018 13:31 ET | Source: Ritter Pharmaceuticals, Inc.

Ritter Pharmaceuticals to Present at 20th Annual HC Wainwright Global Investment Conference on September 5, 2018

LOS ANGELES, Aug. 28, 2018 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of novel therapeutic products that modulate the...
August 14, 2018 16:15 ET | Source: Ritter Pharmaceuticals, Inc.

Ritter Pharmaceuticals Reports Financial Results for the Three and Six Months Ended June 30, 2018 and Recent Progress

LOS ANGELES, Aug. 14, 2018 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of novel therapeutic products that modulate the...
June 27, 2018 07:05 ET | Source: Ritter Pharmaceuticals, Inc.

Ritter Pharmaceuticals Announces Appointment of Andrew J. Ritter as Chief Executive Officer

LOS ANGELES, June 27, 2018 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of innovative therapeutic products that modulate...
June 27, 2018 07:00 ET | Source: Ritter Pharmaceuticals, Inc.

Ritter Pharmaceuticals Initiates First Pivotal Phase 3 Trial for RP-G28 for the Treatment of Lactose Intolerance

Conference Call Today - June 27, 2018 at 4:30 p.m. ET LOS ANGELES , June 27, 2018 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a...
June 05, 2018 08:30 ET | Source: Ritter Pharmaceuticals, Inc.

Ritter Pharmaceuticals Highlights Key Phase 2b Clinical Trial Data of RP-G28 for Lactose Intolerance at Digestive Disease Week 2018

Additional Data Describes Novel Clinical Symptom Assessment Tool Developed in Phase 2b Trial and to be Used in Upcoming Phase 3 Clinical Trial LOS ANGELES, June 05, 2018 (GLOBE NEWSWIRE) -- Ritter...
May 29, 2018 06:00 ET | Source: Ritter Pharmaceuticals, Inc.

Ritter Pharmaceuticals Announces Appointment of John W. Beck as Chief Financial Officer

LOS ANGELES, May 29, 2018 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of novel therapeutic products that modulate the gut...
May 22, 2018 08:30 ET | Source: Ritter Pharmaceuticals, Inc.

Ritter Pharmaceuticals to Present Two Posters at Digestive Disease Week 2018 Highlighting Treatment Data of RP-G28 for Lactose Intolerance

LOS ANGELES, May 22, 2018 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of novel therapeutic products that modulate the gut...
May 15, 2018 16:10 ET | Source: Ritter Pharmaceuticals, Inc.

Ritter Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Business Updates

LOS ANGELES, May 15, 2018 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (NASDAQ:RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of novel therapeutic products that modulate the gut...
May 03, 2018 06:00 ET | Source: Ritter Pharmaceuticals, Inc.

Ritter Pharmaceuticals Selects Medpace as its Clinical Research Organization for Pivotal Phase 3 Clinical Trial of RP-G28 in Lactose Intolerance

LOS ANGELES, May 03, 2018 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of novel therapeutic products that modulate the gut...
March 22, 2018 11:35 ET | Source: Ritter Pharmaceuticals, Inc.

Ritter Pharmaceuticals Announces 1-for-10 Reverse Stock Split

Los Angeles, California, March 22, 2018 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of novel therapeutic products that...